Skip to main content
SpringerLink
Log in

Lymphokines

Progress and Promise

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Altmann A, Katz DH. The biology of monoclonal lymphokines secreted by T cell lines and hybridomas. Advances in Immunology 33: 73–166, 1982

    Article  Google Scholar 

  • Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YCE, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachetin. Nature 316: 552–555, 1985a

    Article  PubMed  CAS  Google Scholar 

  • Beutler B, Milsark W, Cerami A. Passive immunization against cachectin/tumor necrosis factor (TNF) protects mice from the lethal effect of endotoxin. Science 229: 869–871, 1985b

    Article  PubMed  CAS  Google Scholar 

  • Brooks CG, Holscher M, Urdal D. Natural killer activity in cloned cytotoxic T lymphocytes: regulation by interleukin 2, interferon, and specific antigen. Journal of Immunology 135: 1145–1152, 1985

    CAS  Google Scholar 

  • Came PE, Carter WA. Interferon: its application and future as an anti-neoplastic agent. In Ottenbrie RM & Butler GB (Eds) Drugs and the pharmaceutical sciences, Vol. 24, Marcel Dekker, New York, 1983

    Google Scholar 

  • Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proceedings of the National Academy of Sciences (USA) 72: 3666–3673, 1975

    Article  CAS  Google Scholar 

  • Dempsey RA, Dinarello CA, Meir JW, Rosenwasser LJ, Allegretta M, et al. The differential effects of human leukocytic pyrogen/lymphocyte activating factor, T cell growth factor, and interferon on human natural killer activity. Journal of Immunology 129: 2504–2511, 1982

    CAS  Google Scholar 

  • Dinarello CA. Interleukin 1. Reviews of Infectious Diseases 6: 51–955, 1984

    Article  PubMed  CAS  Google Scholar 

  • Donahue RE, Wang EA, Stone DK, Kamen R, Wong GC, et al. Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature 321: 872–875, 1986

    Article  PubMed  CAS  Google Scholar 

  • Farrar JJ, Benjamin WR, Hilfiker ML, Howard M, Farrar WL, et al. The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody forming B cell responses. Immunology 63: 129–209, 1982

    CAS  Google Scholar 

  • Gery I, Gershon RK, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. Journal of Experimental Medicine 136: 128–142, 1972

    Article  PubMed  CAS  Google Scholar 

  • Goeddel DV, Yelverton E, Ulrich A, Heyneker HL, Miozzari CF, et al. Human leukocyte interferon produced by E. coli is biologically active. Nature 287: 411–416, 1980

    Article  PubMed  CAS  Google Scholar 

  • Gowen M, Wood DD, Ihrie EJ, McGuire MKB, Russel RG. An interleukin-1-like factor stimulates bone resorption in vitro. Nature 306: 378–380, 1983

    Article  PubMed  CAS  Google Scholar 

  • Gray PW, Pennica D, Yelverton E, Najarian R, Simonsen CC, et al. Expression of human interferon cDNA in E. coli and monkey cells. Nature 295: 503–508, 1982

    Article  PubMed  CAS  Google Scholar 

  • Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. Journal of Experimental Medicine 155: 1823–1841, 1982

    Article  PubMed  CAS  Google Scholar 

  • Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin-2 augments natural killer cell activity. Nature 291: 225–338, 1981

    Article  Google Scholar 

  • Herrmann F, Cannistra SA, Levine H, Griffin JD. Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. Journal of Experimental Medicine 162: 1111–1116, 1985

    Article  PubMed  CAS  Google Scholar 

  • Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K, et al. Identification of a T cell-derived B cell growth factor distinct from interleukin 2. Journal of Experimental Medicine 155: 914–921, 1982

    Article  PubMed  CAS  Google Scholar 

  • Lane HC, Siegel JP, Rook AH, Masur H, Gelmann EP, et al. Use of interleukin-2 in patients with acquired immunodeficiency syndrome. Journal of Biological Response Modifiers 3: 512–516, 1984

    PubMed  CAS  Google Scholar 

  • Leonard WJ, Depper JM, Uchiyama T, Smith KA, Waldmann TA, et al. A monoclonal antibody that appears to recognise the receptor for human T-cell growth factor, partial characterization of the receptor. Nature 300: 207, 1982

    Article  Google Scholar 

  • March C, Mosley B, Larseh A, et al. Cloning, sequence and expression of two distinct human interleukin 1 complementary DNAs. Nature 315: 641–648, 1985

    Article  PubMed  CAS  Google Scholar 

  • Mazumder A, Rosenberg SA. Successful immunotherapy of killer-resistant established melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. Journal of Experimental Medicine 159: 495–507, 1984

    Article  PubMed  CAS  Google Scholar 

  • Mizel SB, Farrar JJ. Revised nomenclature for antigen-nonspecific T-cell proliferation and helper factors. Cellular Immunology 48: 433–436, 1979

    Article  PubMed  CAS  Google Scholar 

  • Moore RN, Hoffeld JT, Farrar JJ, Mergenhagen SE, Oppenheim JJ, et al. Role of colony-stimulating factors as primary regulators of macrophage functions. Lymphokines 3: 119–148,1981

    CAS  Google Scholar 

  • Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007–1008, 1976

    Article  PubMed  CAS  Google Scholar 

  • Mule JJ, Shu S, Rosenberg SA. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. Journal of Immunology 135: 646–652, 1985

    CAS  Google Scholar 

  • Murphy PA, Simon PL, Willoughby WF. Endogenous pyrogens made by rabbit peritoneal exudate cells are identical with lymphocyte activating factors made by rabbit alveolar macrophages. Journal of Immunology 124: 2498–2503, 1980

    CAS  Google Scholar 

  • Oppenheim JJ, Kovacs EJ, Matsushima K, Durum SK. There is more than one interleukin 1. Immunology Today 7: 45–56, 1986

    Article  CAS  Google Scholar 

  • Ortaldo JR, Mason AT, Gerard JP, Henderson LE, Farrar W, et al. Effects of natural and recombinant IL 2 on regulation of IFN-gamma production and natural killer activity: lack of involvement of the TAC antigen for these immunoregulatory effects. Journal of Immunology 133: 779–783, 1984

    CAS  Google Scholar 

  • Quesada JR, Reuben J, Manning JT, et al. Induction of remission in hairy cell leukemia with alpha interferon. New England Journal of Medicine 310: 15–18, 1984

    Article  PubMed  CAS  Google Scholar 

  • Rocklin RE, Benaltzen K, Greineder D. Mediators of immunity: lymphokines and monotones. Advances in Immunology 29: 55–136, 1980

    Article  PubMed  CAS  Google Scholar 

  • Rook AH, Masur H, Lane HC, Frederick WR, Kasahara T, et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. Journal of Clinical Investigation 72: 398–403, 1983

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA, Lotze MT. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annual Review of Immunology 3: 681–709, 1986

    Article  Google Scholar 

  • Rouse BT, Miller LS, Turtinen L, Moore RN. Augmentation of immunity to herpes simplex virus by in vivo administration of interleukin 2. Journal of Immunology 134: 926–930, 1985

    CAS  Google Scholar 

  • Siegel JP, Lane HC, Stocks NI, Quinnan GV, Fauci A. Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome. Journal of Biological Response Modifiers 4: 596–601, 1985

    PubMed  CAS  Google Scholar 

  • Siegel JP, Rook AH, Djeu JY, Quinnan GV. Interleukin 2 therapy in infectious diseases: rationale and prospects. Infection 12: 298–302,1984

    Article  PubMed  CAS  Google Scholar 

  • Smith KA. T cell growth factor. Immunological Reviews 51: 337–352, 1980

    Article  PubMed  CAS  Google Scholar 

  • Smith KA, Gilbride KT, Fabata MF. Lymphocyte activating factor promotes T cell growth factor production by cloned murine lymphoma cells. Nature 287: 353–355, 1980

    Article  Google Scholar 

  • Sonnenfeld G, Mandel A, Merigan TC. Time and dosage dependence of immunoenhancement by murine type II interferon preparations. Cellular Immunology 40: 285–293, 1978

    Article  PubMed  CAS  Google Scholar 

  • Spiegel RJ. Clinical trials in non-hematologic malignancies. In Kisner DL & Smyth JF (Eds) Interferon-alpha-2: preclinical and clinical evaluation, Martin Nijhoff Publishers, Boston, 1985

    Google Scholar 

  • Stanley ER, Jubinsky PT. Factors affecting the growth and differentiation of haemopoietic cells in culture. Clinics in Haematology 13: 329–348, 1984

    PubMed  CAS  Google Scholar 

  • Stewart WE. The interferon system, Springer Verlag, New York, 1981

    Book  Google Scholar 

  • Svedersky LP, Shepard HM, Spencer SA, Shalaby MR, Palladino MA. Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin 2. Journal of Immunology 126: 2321–2327, 1981

    Google Scholar 

  • Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, et al. Structure and expression of a cloned cDNA for human interleukin 2. Nature 302: 305–310, 1983

    Article  PubMed  CAS  Google Scholar 

  • Taniguchi T, Sakai M, Fuji-Kuriyama Y, Muramatsu M, Kobayashi S, et al. Construction and identification of a bacterial plasmid containing the human fibroblast interferon gene sequence. Proceedings of the Japanese Academy 55B: 464–469, 1979

    Article  Google Scholar 

  • Terry WD, Rosenberg SA. Immunotherapy of human cancer, Elsevier North-Holland, New York, 1982

    Google Scholar 

  • Torti FM, Dieckmann B, Beutler B, Cerami A, Ringold GM. A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science 229: 867–869, 1985

    Article  PubMed  CAS  Google Scholar 

  • Trinchieri G, Perussia B. Immune Interferon: a pleiotropic lymphokine with multiple effects. Immunology Today 6: 133–138, 1985

    Article  Google Scholar 

  • Vilcek J, Gray PW, Rinderknecht E, Sevestopoulos CG. Interferon: a lymphokine for all seasons. Lymphokines 11: 1–32, 1985

    CAS  Google Scholar 

  • Week PK, Cam PE. Comparative biologic activities of human interferons. In Cam PE & Carter WA (Eds) Comparative interferons and their applications, Springer Verlag, New York, 1984

    Google Scholar 

  • Williamson B, Carswell EA, Rubin BY, Prendergast JS, Old LJ. Human TNF produced by human B cell lines: synergistic cytotoxin interaction with human interferon. Proceedings of the National Academy of Sciences 80: 5397–5401, 1983

    Article  CAS  Google Scholar 

  • Wong GC, Witek JA, Temple PA, Wilkens KM, Leary AC, et al. Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 228: 810–815, 1985

    Article  PubMed  CAS  Google Scholar 

  • Zoon KC, Hu R, Zur Nedden D, Gerrard TL, Enterline JC, et al. Further studies on the purification and partial characterization of human lymphoblastoid interferon alphas. In Stewart WE & Schellekens H (Eds) The biology of the interferon system 1985, Elsevier, Amsterdam, 1986

    Google Scholar 

  • Zubler RH, Lowenthal JW, Erard F, Hashimoto N, Devos R, et al. Activated B cells express receptors for, and proliferate in response to, pure interleukin 2. Journal of Experimental Medicine 160: 1170–1183, 1984

    Article  PubMed  CAS  Google Scholar 

  • Zur Nedden D, Gerrard TL, Zoon KC. Activation of human monocyte tumorcidal activity by specifies of human lymphoblastoid interferon alpha. Abstract no. 111–56, ISIR-TNO meeting on the interferon system, Espoo, Finland, 1986

Download references

Author information

Authors and Affiliations

  1. Division of Virology, Office of Biologics Research and Review, Center for Drugs and Biologics, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD, 20892, USA

    David W. Horohov & Jay P. Siegel

Authors
  1. David W. Horohov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jay P. Siegel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horohov, D.W., Siegel, J.P. Lymphokines. Drugs 33, 289–295 (1987). https://doi.org/10.2165/00003495-198733040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198733040-00001

Keywords

Search

Navigation